Combining epigenetic therapy with venetoclax overcomes alemtuzumab resistance in T-cell prolymphocytic leukemia. A case report of a 26-year-old man with a prior history of T-cell acute lymphoblastic leukemia and GI-T lymphoma

Lymphoma
25/09/2020

Acta Oncol. 2020 Sep 24:1-5. doi: 10.1080/0284186X.2020.1821913. Online ahead of print.

NO ABSTRACT